Cisplatin-induced non-apoptotic death of pancreatic cancer cells requires mitochondrial cyclophilin-D-p53 signaling

Biochemical and Biophysical Research Communications

Volumn 437, Issue 4, 2013, Pages 526-531

  Chen, Bo ^a   Xu, Ming ^a   Zhang, Hui ^a   Wang, Jing xu ^a   Zheng, Ping ^a   Gong, Lei ^b   Wu, Gao jue ^b   Dai, Tu ^b  

^a Key Laboratory of Arrhythmias of Ministry of Education   (China)

^b WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

Cyclophilin D; Mitochondrion and cell death; P53; Pancreatic cancer

Indexed keywords

CAMPTOTHECIN; CISPLATIN; CYCLOPHILIN D; CYCLOSPORIN A; PROTEIN P53; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

3-[4,5-DIMETHYLTHYLTHIAZOL-2-YL]-2,5 DIPHENYLTETRAZOLIUM BROMIDE; CAMPTOTHECIN; CMT; CSA; CYCLOPHILIN D; CYCLOPHILIN-D; CYCLOSPORINE A; CYP-D; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRION AND CELL DEATH; MPTP; MTT; P53; PANCREATIC CANCER;

APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; CYCLOPHILINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MITOCHONDRIA; NECROSIS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881556852     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.103     Document Type: Article

References (22)

1. Rosewicz S., Wiedenmann B. Pancreatic carcinoma. Lancet 1997, 349:485-489.
2. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Carteni G., Massidda B., Dapretto E., Manzione L., Piazza E., Sannicolo M., Ciaparrone M., Cavanna L., Giuliani F., Maiello E., Testa A., Pederzoli P., Falconi M., Gallo C., Di Maio M., Perrone F. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J. Clin. Oncol. 2010, 28:1645-1651.
3. Jenks S. AACR highlights: promise for treating pancreatic cancer. J. Natl. Cancer Inst. 2011, 103:786-787.
4. Costello E., Neoptolemos J.P. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat. Rev. Gastroenterol. Hepatol. 2010, 8(2011):71-73.
5. Wong H.H., Lemoine N.R. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:412-422.
6. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schonekas H., Rost A., Neuhaus H., Haag C., Clemens M., Heinrich B., Vehling-Kaiser U., Fuchs M., Fleckenstein D., Gesierich W., Uthgenannt D., Einsele H., Holstege A., Hinke A., Schalhorn A., Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 2006, 24:3946-3952.
7. Banerjee S., Zhang Y., Wang Z., Che M., Chiao P.J., Abbruzzese J.L., Sarkar F.H. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int. J. Cancer 2007, 120:906-917.
8. Symon Z., Davis M., McGinn C.J., Zalupski M.M., Lawrence T.S. Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53:140-145.
9. Bragado P., Armesilla A., Silva A., Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742.
10. Zhang M., Liu W., Ding D., Salvi R. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 2003, 120:191-205.
11. Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012, 149:1536-1548.
12. Baumann K. Cell death: multitasking p53 promotes necrosis. Nat. Rev. Mol. Cell Biol. 2012, 13:480-481.
13. Ji C., Yang B., Yang Z., Tu Y., Yang Y.L., He L., Bi Z.G. Ultra-violet B (UVB)-induced skin cell death occurs through a cyclophilin D intrinsic signaling pathway. Biochem. Biophys. Res. Commun. 2012, 425:825-829.
14. Wu C.-H., Cao C., Kim J.H., Hsu C.-H., Wanebo H.J., Bowen W.D., Xu J., Marshall J. Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett. 2012, 12:5475-5480.
15. Javadov S., Kuznetsov A. Mitochondrial permeability transition and cell death: the role of cyclophilin D. Front. Physiol. 2013, 4:76.
16. Baines C.P. The molecular composition of the mitochondrial permeability transition pore. J. Mol. Cell. Cardiol. 2009, 46:850-857.
17. Du H., Guo L., Fang F., Chen D., Sosunov A.A., McKhann G.M., Yan Y., Wang C., Zhang H., Molkentin J.D., Gunn-Moore F.J., Vonsattel J.P., Arancio O., Chen J.X., Yan S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med. 2008, 14:1097-1105.
18. Du H., Guo L., Zhang W., Rydzewska M., Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol. Aging 2011, 32:398-406.
19. Crunkhorn S. Anticancer drugs: stapled peptide rescues p53. Nat. Rev. Drug Discov. 2011, 10:21.
20. Yang C., Kaushal V., Haun R.S., Seth R., Shah S.V., Kaushal G.P. Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ. 2008, 15:530-544.
21. Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C., Neoptolemos J., Williamson R.C., et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 1991, 64:1076-1082.
22. Mohiuddin M., Chendil D., Dey S., Alcock R.A., Regine W., Ahmed M.M. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells. Anticancer Res. 2002, 22:825-830.